Thanatophoric dysplasia

Common Name(s)

Thanatophoric dysplasia, Thanatophoric dysplasia type 1 (TD1), Thanatophoric dysplasia type 2 (TD2)

Thanatophoric dysplasia (TD) is a rare, severe skeletal condition. The condition is congenital meaning a baby is born with the condition. TD results from a change in the baby’s DNA or genes (genetic). A baby born with TD will have underdeveloped bones and lungs. This condition is typically diagnosed during pregnancy during an ultrasound exam. Further genetic tests of the baby can determine the genetic mutation.

Symptoms of TD may include very short limbs, extra folds of skin, large head and forehead, shortened ribs, and underdeveloped lungs. There are two types of this condition. Thanatophoric dysplasia type 1 (TD1) is the more common type. With TD1, the leg bones (femurs) are typically curved and the baby has a normal shaped skull. Thanatophoric dysplasia type 2 (TD2) is less common. With TD2, the baby has straight leg bones, but a cloverleaf-shaped skull. Sadly, babies with both types of this condition are stillborn or pass away a short time after birth. There have been reported cases where the baby has lived slightly longer with the help of medical intervention.

The cause of both types of TD is an error (mutation) in a gene located on chromosome 4. The gene, named fibroblast growth factor receptor 3 (FGFR3), is responsible for bone and brain tissue development. When altered, the gene cannot pass along the information to make bones of the right length. This condition arises by random chance (de novo), meaning that the parents do not have the error in their own gene. Therefore, the risk of the couple having another child with this condition is low.

Unfortunately, there is no cure for TD at this time. This is a very serious condition and parents often struggle with the emotional tolls of facing this diagnosis. Therefore, if your baby has been diagnosed with thanatophoric dysplasia, it is helpful to speak with a doctor, genetic counselor, or therapist to gain information about the condition and support.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Thanatophoric dysplasia" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Thanatophoric dysplasia" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Thanatophoric dysplasia" returned 31 free, full-text research articles on human participants. First 3 results:

Effect of thanatophoric dysplasia type I mutations on FGFR3 dimerization.
 

Author(s): Nuala Del Piccolo, Jesse Placone, Kalina Hristova

Journal: Biophys. J.. 2015 Jan;108(2):272-8.

 

Thanatophoric dysplasia type I (TDI) is a lethal human skeletal growth disorder with a prevalence of 1 in 20,000 to 1 in 50,000 births. TDI is known to arise because of five different mutations, all involving the substitution of an amino acid with a cysteine in fibroblast growth factor ...

Last Updated: 22 Jan 2015

Go To URL
Temporal lobe dysplasia: a characteristic sonographic finding in thanatophoric dysplasia.
 

Author(s): D C Wang, P Shannon, A Toi, D Chitayat, U Mohan, E Barkova, S Keating, G Tomlinson, P Glanc

Journal: Ultrasound Obstet Gynecol. 2014 Nov;44(5):588-94.

 

To determine the incidence of temporal lobe dysplasia (TLD) detected on prenatal ultrasound in thanatophoric dysplasia (TD) over an 11-year period in a tertiary referral center.

Last Updated: 3 Nov 2014

Go To URL
Rapid detection of K650E mutation in FGFR3 using uncultured amniocytes in a pregnancy affected with fetal cloverleaf skull, occipital pseudoencephalocele, ventriculomegaly, straight short femurs, and thanatophoric dysplasia type II.
 

Author(s): Chih-Ping Chen, Tung-Yao Chang, Ming-Huei Lin, Schu-Rern Chern, Jun-Wei Su, Wayseen Wang

Journal: Taiwan J Obstet Gynecol. 2013 Sep;52(3):420-5.

 

To present the ultrasound and molecular genetic diagnosis of thanatophoric dysplasia type II (TD2).

Last Updated: 30 Sep 2013

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Thanatophoric dysplasia" returned 1 free, full-text review articles on human participants. First 3 results:

Antenatal sonographic diagnosis of thanatophoric dysplasia: a report of three cases and a review of the literature with special emphasis on the differential diagnosis.
 

Author(s): R L Schild, G H Hunt, J Moore, H Davies, D H Horwell

Journal: Ultrasound Obstet Gynecol. 1996 Jul;8(1):62-7.

 

A series of three cases is reported in which the diagnosis of thanatophoric dysplasia was reached at routine mid-trimester scanning in a District General Hospital. All three patients underwent termination of pregnancy with the diagnosis of thanatophoric dysplasia confirmed by postmortem ...

Last Updated: 26 Dec 1996

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Last Updated: 27 Jan 2016

Go to URL